Aytu BioPharma Inc. (AYTU)
NASDAQ: AYTUHealthcareDrug Manufacturers - Specialty & GenericUSD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
AYTU stock chart
Technical analysisKey statistics
All statistics- Market cap
- $22.28M
- Forward P/E
- 13.23
- EPS (TTM)
- -$1.16
- Dividend yield
- None
- 52-week range
- 1.80 – 3.07
- Day range
- 2.05 – 2.09
- Volume / Avg
- 5.62K / 34.40K
- Beta
- —
- Shares outstanding
- 10.87M
52-week range
AYTU stock today
Aytu BioPharma (AYTU) closed at $2.05 on Oct 8, essentially unchanged from the prior close, versus the S&P 500's 0.47% decline. Trading was light, with 5.62K shares changing hands, about 16% of the average daily volume. Shares are 33.2% below their 52-week high of $3.07, set on Jan 5, 2026 and 13.9% above the 52-week low of $1.80, near the bottom of the past year's range.
AYTU is down 21.2% year to date, underperforming the S&P 500 (+13.5%). Over the past 12 months, the stock has lost 13.5%. Aytu BioPharma has posted a net loss over the last twelve months (EPS of -$1.16), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Aytu BioPharma
Company profileAytu BioPharma, Inc., a pharmaceutical company, focuses on commercializing novel therapeutics in the United States and internationally. The company offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT extended-release orally disintegrating tablets for patients from six years of age and above; Cotempla XR-ODT A central nervous system stimulant indicated for the treatment of ADHD in patients 6 to 17 years of age; and Metadate CD, a central nervous system stimulant indicated for the treatment of ADHD in patients 6 to 15 years of age. It also provides pediatric prescription product portfolio comprising Karbinal ER, an extended-release carbinoxamine (antihistamine) suspension indicated to treat numerous allergic conditions for patients two years and above.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Mr. Joshua R. Disbrow
- Headquarters
- Denver, CO
- Employees
- 75
- Website
- aytubio.com
Analyst forecast
ForecastConsensus (3 analysts)
strong_buy
Avg. price target
$9.67+371.71%
- Strong buy 1
- Buy 2
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Aytu BioPharma peers
Healthcare sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| TXMDTherapeuticsMD Inc. | 2.01 | +0.50% | $23.26M | vs AYTU |
| OPTHOptimi Health Corp. | 4.09 | 0.00% | $23.39M | vs AYTU |
| UPCUniverse Pharmaceuticals Inc. Class A | 4.18 | -5.00% | $21.00M | vs AYTU |
| SHPHShuttle Pharmaceuticals Holdings Inc. | 5.55 | +17.83% | $26.44M | vs AYTU |
| BFRIBiofrontera Inc. | 0.9188 | -1.77% | $13.65M | vs AYTU |
| RMTIRockwell Medical Inc. | 8.02 | -2.43% | $32.32M | vs AYTU |
| CABRCaring Brands Inc. | 1.16 | -4.92% | $12.03M | vs AYTU |
| APUSApimeds Pharmaceuticals US Inc. | 5.51 | -21.84% | $8.32M | vs AYTU |
Indexes, lists and sector
Appears in lists
Aytu BioPharma stock FAQ
What is Aytu BioPharma's stock price today?
AYTU last traded at $2.05 as of Oct 8, 4:00 PM EDT, up 0.00% on the day. Prices are delayed at least 15 minutes.
Does Aytu BioPharma pay a dividend?
No. Aytu BioPharma does not currently pay a regular cash dividend.
Who is Aytu BioPharma's CEO?
Mr. Joshua R. Disbrow is the chief executive officer of Aytu BioPharma Inc., which has about 75 employees.
Has AYTU ever split its stock?
Yes. The most recent AYTU stock split was a 1-for-20 split on Jan 6, 2023, one of 6 splits on record.
What is the AYTU 52-week high?
The 52-week high for AYTU is $3.07 and the 52-week low is $1.80. The stock is currently 33.2% below its high.